We quantified the relative ability of somatic variants from donors from which multiple broadly neutralizing antibodies have been isolated to recognize the glycan V3-supersite transplants. Similar ratios of recognition were observed for all 11 transplants with positive ELISA recognition of PGT128. Notably, these ratios correlated with the percentage of the epitope contributed by the mini-V3. Altogether these results indicate that the ability of the glycan V3-site transplants to recapitulate recognition by template broadly neutralizing antibodies correlates with Grosvenorine the transplanted portion of the epitope. Despite retaining less than 50% of the supersite, glycan V3 transplants may still have nM affinity to the target antibodies. Finally we asked how the placements of the transplants into nanoparticle contexts might alter the recognition by the target antibodies. Because nanoparticles have shown utility in enhancing both antigenicity and immunogenicity and because the small, rigid proteins identified as suitable acceptor scaffolds for the glycan V3-supersite of vulnerability might be also suitable for presentation on a virus-like particle or other multivalent platforms, we transplanted the glycan V3-supersites into the ferritin nanoparticle context. The ferritin from H. pylori has octahedral symmetry and assembles into a nanoparticle of 24 subunits,Mogroside-IIA2 arrayed as 8 trimers, and placement of influenza hemagglutinin in this context was shown to enhance immunogenicity by over 10-fold. When tested by surface plasmon resonance, the glycan V3-supersite transplants in the ferritin nanoparticle context retained their ability to bind to broadly neutralizing antibodies. Notably, the off-rate of the interaction with antibodies was reduced in the ferritin nanoparticle context relative to the native immunogen. VL is characterized by prolonged fever, hepatosplenomegaly, anaemia, weightloss, cachexia, pancytopenia, hypergammaglobulinemia and suppressed cellular immune response. Due to the nonavailability of an ideal antileishmanial drug 350 million people are globally at the risk of acquiring infection with Leishmania parasites worldwide.